ASH 2022 | Microenvironment features associated with MRD negativity in patients with myeloma treated with DKRd
Eileen Boyle, MD, PhD, NYU Langone, New York City, NY, comments on the results of a study examinating the determinants of response in patients with multiple myeloma who do not achieve measurable residual disease (MRD) negativity after treatment with immunotherapy. Overall, the study revealed that patients who were MRD-negative had a highly different microenvironment composition in comparison to patients who were MRD-positive, suggesting that manipulating these components could improve the depth of response to therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
